Abstract

BackgroundBasal cell carcinoma is the most common skin cancer worldwide. Treatment options include both surgical and topical modalities. Although risk of metastasis is low, basal cell carcinoma can be invasive and infiltrate important underlying structures such as bone or cartilage. While many clinical trials examining therapies for basal cell carcinoma exist, the lack of consensus in outcome reporting across all trials poses a concern. Proper evaluation and comparison of treatment modalities is challenging. In order to address the inconsistencies present, this project aims to determine a core set of outcomes which should be evaluated in all clinical trials of basal cell carcinoma.Methods/designOutcomes will be extracted over four phases: (1) a systematic literature review, (2) patient interviews, (3) other published sources, and (4) stakeholder involvement. Potential outcomes will then be examined by the Steering Committee, who may add or remove outcomes. The Delphi process will then be performed to condense the list of outcomes generated. Two rounds of Delphi surveys will be performed with two groups of participants – physicians and patients. A consensus meeting with relevant stakeholders will be conducted after the Delphi exercise to further select outcomes, taking into account participant scores. By the end of the meeting, members will vote and decide on a final recommended set of core outcomes. For the duration of the study, we will be in collaboration with both the Core Outcome Measures in Effectiveness Trials (COMET) initiative and the Cochrane Skin Group – Core Outcome Set Initiative (CSG-COUSIN).DiscussionThis study aims to develop a core outcome set to guide assessment in clinical trials on basal cell carcinoma. The end-goal is to improve the consistency of outcome reporting and allow proper evaluation of treatment effectiveness.

Highlights

  • Basal cell carcinoma is the most common skin cancer worldwide

  • This study aims to develop a core outcome set to guide assessment in clinical trials on basal cell carcinoma

  • The end-goal is to improve the consistency of outcome reporting and allow proper evaluation of treatment effectiveness

Read more

Summary

Discussion

There has been no COS developed relating to BCC. With a lack of standardization in outcomes assessed, the potential for reporting bias exists. Selection of outcomes is crucial for properly comparing and evaluating different treatment modalities. The proposed COS for BCC aims to reduce the inconsistency of outcomes and outcome measurements across relevant trials. By reporting outcomes which are important, we hope to develop an accepted COS to be utilized in future trials and clinical practice. Trial status The development of the COS is active and ongoing in its initial phase of outcome extraction

Background
Objective
Findings
Availability of data and materials Not applicable
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call